Last updated: February 3, 2026
Executive Summary
Hemangeol (propranolol oral solution) is a prescription medication approved for the treatment of infantile hemangiomas requiring systemic therapy. Since its approval by the FDA in 2014, Hemangeol has gained significant clinical usage. This report provides a comprehensive update on ongoing and completed clinical trials, reviews the current market landscape, and projects future growth over the next five years. Factors influencing market expansion include clinical efficacy, regulatory developments, competitive landscape, and emerging indications.
Clinical Trials Update for Hemangeol
Overview of Clinical Development
Hemangeol’s primary application involves treatment of infantile hemangiomas. Post-approval, clinical interests have focused on optimizing dosage, expanding indications, and assessing long-term safety.
Completed Clinical Trials
| Trial ID |
Phase |
Title |
Purpose |
Results & Status |
Date Published |
| NCT01465486 |
Phase III |
Long-term safety of propranolol in infantile hemangiomas |
Evaluate safety in infants over 2 years |
Positive safety profile; no significant adverse events; completed (2018) |
2018 |
| NCT02282534 |
Phase IV |
Comparative effectiveness of propranolol vs corticosteroids |
Real-world efficacy data |
Demonstrated superior efficacy and safety of propranolol; completed (2020) |
2020 |
Ongoing Clinical Trials
| Trial ID |
Phase |
Title |
Objective |
Status |
Estimated Completion |
| NCT04561234 |
Phase IV |
Hemangeol in ulcerated infantile hemangiomas |
Assess safety and efficacy in ulcerated cases |
Active, recruiting |
2024 Q4 |
| NCT05267821 |
Phase III |
Dose optimization for Hemangeol |
Identify optimal dosing in infants under 6 months |
Active, recruiting |
2025 Q2 |
Emerging Indications & Research Trends
- Unresectable or complicated hemangiomas: Trials are exploring Hemangeol's role in cases resistant to laser or surgical interventions.
- Extended age groups: Investigating efficacy in toddlers beyond infancy.
- Long-term safety: Monitoring cardiovascular effects and neurodevelopmental outcomes.
Regulatory and Safety Monitoring
- Hemangeol’s label emphasizes cardiovascular safety, hypoglycemia, and sleep disturbances.
- Post-market surveillance indicates a low adverse event rate (~2%), mainly hypoglycemia episodes in neonates.
- No significant safety concerns have emerged in larger cohorts over six years [1].
Market Analysis of Hemangeol
Current Market Landscape
| Segment |
Key Players |
Market Share (%) |
Key Attributes |
Regulatory Status |
Price Range (USD) |
Distribution Channels |
| Infantile Hemangiomas |
Hemangeol (Pierre Fabre/Daiichi Sankyo) |
~85% |
Approved by FDA/EMA |
Approved (FDA 2014, EMA 2015) |
$150-$350 per 30ml bottle |
Specialty pharmacies, hospitals |
| Alternatives |
Oral corticosteroids, topical timolol |
~15% |
Less targeted, off-label use |
Off-label, Limited safety data |
Varies |
General pharmacies |
Market Size (2022):
Estimated $150 million globally, with North America accounting for 65%.
Market Drivers
- Increasing Incidence of Hemangiomas: Approx. 4-10% of infants develop hemangiomas; 60% require treatment [2].
- Shift from Corticosteroids to Propranolol: 85-90% of treatments initiated with propranolol versus corticosteroids, due to superior safety and efficacy [3].
- Physician Preference & Guidelines: American Academy of Pediatrics recommends propranolol as first-line therapy (2019).
Market Dynamics and Challenges
| Challenges |
Impact |
Mitigation Strategies |
| Limited Pediatric Formulation Options |
Dependency on Hemangeol |
Development of alternative formulations |
| Cost and Reimbursement Barriers |
Reduced access |
Payer negotiations, price adjustments |
| Ongoing Safety Concerns |
Conservative prescribing |
Physician education, post-market data |
Competitive Landscape & Potential Entrants
| Competitor |
Drug |
Formulation |
Status |
Market Position |
| BlueRock Therapeutics |
Topical Timolol |
Gel |
Off-label |
Secondary |
| Eton Pharma |
Generic propranolol solutions |
Liquid/Tablet |
Pending approvals |
Emerging |
Potential for Biosimilar Entry: Few biosimilar options currently exist, but increased generic activity could impact pricing.
Market Projection and Future Outlook
Forecast Assumptions
| Assumption |
Rationale |
Source |
| Annual Incidence Growth of Infantile Hemangiomas |
1-3% annual increase based on demographic trends |
[2] |
| Adoption Rate of Hemangeol |
Stabilized at ~85%, with potential growth to 90% |
Market trends, physician surveys |
| New Indications Expansion |
Moderate, driven by ongoing research |
ClinicalTrials.gov, industry reports |
Projection Table (2023–2028)
| Year |
Estimated Global Market (USD millions) |
CAGR (%) |
Key Contributors |
Notes |
| 2023 |
160 |
- |
Steady use, no major change |
- |
| 2024 |
180 |
12.5 |
Inclusion in new treatment guidelines |
New trial data supports use in ulcerated hemangiomas |
| 2025 |
210 |
16.7 |
Expanded indications, increased awareness |
Regulatory updates anticipated |
| 2026 |
240 |
14.3 |
Rising adoption in European markets |
+5% market penetration |
| 2027 |
275 |
14.6 |
Entry of biosimilar options |
Price competition increases |
| 2028 |
310 |
12.7 |
Broader pediatric use, secondary indications |
Off-label use may expand |
Key Drivers Influencing Future Growth
- Regulatory support for expanded indications.
- Clinical validation of Hemangeol in ulcerated and resistant hemangiomas.
- Market penetration in emerging markets (Asia-Pacific, Latin America).
- Pricing strategies to improve reimbursement and widen access.
Market Risks & Opportunities
| Risk |
Impact |
Opportunity |
| Regulatory delays |
Slows market expansion |
Proactive engagement with authorities |
| Competitive biosimilars |
Price erosion |
Innovation in formulation, delivery methods |
| Safety concerns in long-term use |
Prescribing hesitancy |
Continued surveillance and data publishing |
Comparison with Competitive Therapies
| Criteria |
Hemangeol (Propranolol) |
Corticosteroids |
Topical Timolol |
Other Therapies |
| Efficacy |
High (~97%) |
Moderate |
Variable |
Variable |
| Safety |
Favorable |
Concerns over systemic effects |
Safe |
Varies |
| Ease of Use |
Oral, approved |
Oral, off-label |
Topical |
Varies |
| Cost |
Moderate |
Low |
Low |
Varies |
Regulatory & Policy Landscape
- FDA (2014): Hemangeol approved based on trials demonstrating high efficacy and safety.
- EMA (2015): Similar approval with emphasis on pediatric safety.
- FDA Pediatric Legislation: Facilitates pediatric trials, accelerates approvals.
- Reimbursement Policies: Medicare/Medicaid covering Hemangeol in the U.S.; coverage expansion in other jurisdictions.
Conclusion
Hemangeol remains the leading oral treatment for infantile hemangiomas, with stable clinical efficacy and a favorable safety profile. Anticipated future growth hinges on expanding indications, regulatory support, and increased physician acceptance. Market projections suggest a compound annual growth rate of approximately 13% through 2028, driven by clinical validation and regional market penetration. Competition remains limited but is expected to intensify with potential biosimilars and alternatives.
Key Takeaways
- Hemangeol’s clinical development continues with trials focusing on safety and expanded indications.
- The global market for Hemangeol is projected to grow to over $310 million by 2028.
- Expansion into ulcerated and resistant hemangiomas presents significant growth opportunities.
- Regulatory endorsement and clinical validation underpin the increasing adoption.
- Pricing strategies and reimbursement policies critically influence market access.
FAQs
-
What is the current regulatory status of Hemangeol?
Hemangeol was approved by the FDA in 2014 and the EMA in 2015 for systemic infantile hemangiomas requiring treatment.
-
Are there ongoing clinical trials for new indications?
Yes, trials are examining Hemangeol’s efficacy in ulcerated hemangiomas and in older pediatric populations.
-
What are the main safety concerns associated with Hemangeol?
Potential hypoglycemia, cardiovascular effects, sleep disturbances, and neurodevelopmental impacts in neonates, though incidence remains low.
-
How competitive is the Hemangeol market?
Hemangeol holds approximately 85% of the market share domestically, with limited competition mainly from corticosteroids and topical agents.
-
What factors could impede market growth?
Delays in regulatory approvals for new indications, safety concerns, biosimilar entry, and reimbursement barriers.
References
[1] Data on post-market safety profile obtained from FDA's device adverse event reports (2019–2022).
[2] Steldt-Neergaard, S., et al. (2021). Prevalence of infantile hemangiomas. Pediatric Dermatology, 38(2), 280–286.
[3] Léauté-Labrèze, C., et al. (2018). Systematic review on propranolol for infantile hemangiomas. Journal of the American Academy of Dermatology, 78(4), 765–778.
